Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function

Sponsor
University Hospital, Basel, Switzerland
Study ID
NCT06608433
Status
Completed

Conditions

  • Adrenal Insufficiency
  • Cortisol Deficiency
  • HPA
  • Healthy Volunteer Study

Eligibility Criteria

Sex
MALE
Age
18 Years - 60 Years
Healthy Volunteers
Accepted

Interventions

  • semaglutide — DRUG
    semaglutide/Rybelsus will be administered as a single oral dose
  • Placebo — DRUG
    Placebo pills will be administered as a single oral dose

Study Details

This study aims to investigate the effects of a single dose of the glucagon-like 1 receptor agonist semaglutdie/Rybelsus on the hypothalamo-pituitary-adrenal axis, thus cortisol levels and other stresshormones in healthy males.

Key Dates

Start date
Jan 16, 2025
Status verified
Feb 2026
Primary completion
Oct 31, 2025
Completion
Nov 30, 2025

Study Design

Enrollment
22 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER

Arms

  • Experimental: Semaglutide/Rybelsus
  • Placebo Comparator: Placebo

Primary Outcome Measure

Change in serum cortisol after Rybelsus vs. Placebo [ Time Frame: within 210 minutes after the intake of the study drug ]

Related Studies